Clinical trials
The advance of highly innovative, increasingly personalized therapies in hematology requires novel clinical trial designs and more flexible, adaptive regulatory frameworks and improved data generation to support decision making both during and after clinical studies. Improving the quality, patient centricity and efficiency of clinical trials and better facilitation of academic investigators and patient involvement are priority objectives for EHA in working with regulators, sponsors, clinical research organizations and other stakeholders.
For information about the EHA-led Coalition for Reducing Bureaucracy in Clinical Trials, see bureaucracyincts.eu.
Back